{"id":387352,"date":"2020-11-24T06:03:22","date_gmt":"2020-11-24T11:03:22","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=387352"},"modified":"2020-11-24T06:03:22","modified_gmt":"2020-11-24T11:03:22","slug":"immuron-receives-aud-358280-rd-tax-concession-refund","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-receives-aud-358280-rd-tax-concession-refund\/","title":{"rendered":"Immuron Receives AUD $358,280 R&D Tax Concession Refund"},"content":{"rendered":"
\n

MELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, is pleased to announce that under the Australian Government\u2019s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD $358,280 for eligible research and development expenditure incurred during the 2020 Financial Year.<\/p>\n

This release has been authorised by the directors of Immuron Limited.<\/p>\n\n\n
\n COMPANY CONTACT:<\/strong>
\n
\n Jerry Kanellos, Ph.D.<\/strong>
\n
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n About Immuron<\/strong>
\n
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology platform with one commercial asset generating revenue. In Australia, Travelan\u00ae<\/sup> is a listed medicine on the Australian Register of Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travellers\u2019 Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan\u00ae<\/sup> is a licenced natural health product (NPN 80046016) and is indicated to reduce the risk of Travellers\u2019 Diarrhea. In the U.S., Travelan\u00ae<\/sup> is sold as a dietary supplement for digestive tract protection in accordance with section 403 (r)(6) of the Federal Drug Administration (FDA).<\/p>\n

For more information visit: http:\/\/www.immuron.com<\/a><\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

MELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, is pleased to announce that under the Australian Government\u2019s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD $358,280 for eligible research and development expenditure incurred during the 2020 Financial Year. This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT: Jerry Kanellos, Ph.D. Chief Executive OfficerPh: +61 (0)3 9824 5254info@immuron.com\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 About Immuron Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment … <\/p>\n

Continue reading “Immuron Receives AUD $358,280 R&D Tax Concession Refund”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-387352","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nImmuron Receives AUD $358,280 R&D Tax Concession Refund - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-receives-aud-358280-rd-tax-concession-refund\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immuron Receives AUD $358,280 R&D Tax Concession Refund - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, is pleased to announce that under the Australian Government\u2019s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD $358,280 for eligible research and development expenditure incurred during the 2020 Financial Year. This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT: Jerry Kanellos, Ph.D. Chief Executive OfficerPh: +61 (0)3 9824 5254info@immuron.com\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 About Immuron Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment … Continue reading "Immuron Receives AUD $358,280 R&D Tax Concession Refund"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-receives-aud-358280-rd-tax-concession-refund\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-24T11:03:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTE0NyMzODQxMTI0IzIwMjAyOTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-receives-aud-358280-rd-tax-concession-refund\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-receives-aud-358280-rd-tax-concession-refund\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immuron Receives AUD $358,280 R&D Tax Concession Refund\",\"datePublished\":\"2020-11-24T11:03:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-receives-aud-358280-rd-tax-concession-refund\\\/\"},\"wordCount\":236,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-receives-aud-358280-rd-tax-concession-refund\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTE0NyMzODQxMTI0IzIwMjAyOTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-receives-aud-358280-rd-tax-concession-refund\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-receives-aud-358280-rd-tax-concession-refund\\\/\",\"name\":\"Immuron Receives AUD $358,280 R&D Tax Concession Refund - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-receives-aud-358280-rd-tax-concession-refund\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-receives-aud-358280-rd-tax-concession-refund\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTE0NyMzODQxMTI0IzIwMjAyOTM=\",\"datePublished\":\"2020-11-24T11:03:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-receives-aud-358280-rd-tax-concession-refund\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-receives-aud-358280-rd-tax-concession-refund\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-receives-aud-358280-rd-tax-concession-refund\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTE0NyMzODQxMTI0IzIwMjAyOTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTE0NyMzODQxMTI0IzIwMjAyOTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-receives-aud-358280-rd-tax-concession-refund\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immuron Receives AUD $358,280 R&D Tax Concession Refund\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immuron Receives AUD $358,280 R&D Tax Concession Refund - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-receives-aud-358280-rd-tax-concession-refund\/","og_locale":"en_US","og_type":"article","og_title":"Immuron Receives AUD $358,280 R&D Tax Concession Refund - Market Newsdesk","og_description":"MELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, is pleased to announce that under the Australian Government\u2019s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD $358,280 for eligible research and development expenditure incurred during the 2020 Financial Year. This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT: Jerry Kanellos, Ph.D. Chief Executive OfficerPh: +61 (0)3 9824 5254info@immuron.com\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 About Immuron Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment … Continue reading \"Immuron Receives AUD $358,280 R&D Tax Concession Refund\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-receives-aud-358280-rd-tax-concession-refund\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-24T11:03:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTE0NyMzODQxMTI0IzIwMjAyOTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-receives-aud-358280-rd-tax-concession-refund\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-receives-aud-358280-rd-tax-concession-refund\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immuron Receives AUD $358,280 R&D Tax Concession Refund","datePublished":"2020-11-24T11:03:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-receives-aud-358280-rd-tax-concession-refund\/"},"wordCount":236,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-receives-aud-358280-rd-tax-concession-refund\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTE0NyMzODQxMTI0IzIwMjAyOTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-receives-aud-358280-rd-tax-concession-refund\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-receives-aud-358280-rd-tax-concession-refund\/","name":"Immuron Receives AUD $358,280 R&D Tax Concession Refund - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-receives-aud-358280-rd-tax-concession-refund\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-receives-aud-358280-rd-tax-concession-refund\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTE0NyMzODQxMTI0IzIwMjAyOTM=","datePublished":"2020-11-24T11:03:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-receives-aud-358280-rd-tax-concession-refund\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immuron-receives-aud-358280-rd-tax-concession-refund\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-receives-aud-358280-rd-tax-concession-refund\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTE0NyMzODQxMTI0IzIwMjAyOTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTE0NyMzODQxMTI0IzIwMjAyOTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-receives-aud-358280-rd-tax-concession-refund\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immuron Receives AUD $358,280 R&D Tax Concession Refund"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387352","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=387352"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387352\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=387352"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=387352"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=387352"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}